Biodena Care optimizes cancer management
A simple and accessible test
In 2003, our R&D team discovered the essential role of the hPG80 protein in cancer progression.
From this discovery, which came from French research, we developed a practical and affordable blood test: DxPG80.
DxPG80: a new device to lead the fight against cancer
Through a simple blood test, the DxPG80 test reveals the presence of hPG80, a biomarker specifically associated with cancer diagnosis.
French research excellence at the service of patients
Proposing a more efficient support
The reliable and reproducible DxPG80 test contributes to the optimization of the oncology patient journey.
The incidence of cancer is growing inexorably, it is time to act practically
19.3 million
28.4 million
200 billion €
new cases in 2020
new cases forecasted in 2040
EU and US treatment cost in 2017
Cancer: earlier detection, greater chance of remission
Sources : WHO and Cancer Atlas
Our ambition:
innovation at the service of the patient
Tomorrow, we will become a key player in the overall management of cancer patients in termes of:
-
Early diagnosis
-
Localization
Therapeutic strategy for patients with a first-in-class therapeutic antibody.